Русские видео

Сейчас в тренде

Иностранные видео


Скачать с ютуб Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Explained by Neurologist в хорошем качестве

Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Explained by Neurologist 1 год назад


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса savevideohd.ru



Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Explained by Neurologist

Is it hype or hope? The Bruton's tyrosine kinase inhibitors have been purported to benefit "smouldering" multiple sclerosis. In this video, I explain how drugs like masitinib, tolebrutinib, evobrutinib, and fenebrutinib work. We review the side effects and data from clinical trials. 2012 masitinib progressive MS pilot study: https://bmcneurol.biomedcentral.com/a... Review of emerging MS therapeutics: https://www.ncbi.nlm.nih.gov/pmc/arti... The role of mast cells on the blood brain barrier: https://pubmed.ncbi.nlm.nih.gov/26004... AB science press release of the phase 2B/3 study on masitinib in progressive MS: https://www.globenewswire.com/news-re... Article on the masitinib from the Barts MS blog: https://multiple-sclerosis-research.o... Abstract from Dr. Vermersch about the phase II trial: https://cslide.ctimeetingtech.com/msd... MS news today article on masitinib: https://multiplesclerosisnewstoday.co... Product label of MASIVET: https://www.ema.europa.eu/en/document... Tyrosine Kinase Pathway: https://www.researchgate.net/figure/S... A diagram showing the potential role of Bruton’s Tyrosine Kinase inhibiting drugs (tolebrutinib, evobrutinib, masitinib) in Multiple Sclerosis: https://link.springer.com/article/10.... Evobrutinib Efficacy is Maintained Over Two Years in an Open-label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis (4124): https://n.neurology.org/content/96/15... lacebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis: https://www.nejm.org/doi/full/10.1056... Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial: https://www.thelancet.com/journals/la... Comment or ask questions below! I would be happy to answer! Subscribe on YouTube for more videos every Wednesday! Make video requests in the comments section! Check out my book “Resilience in the Face of Multiple Sclerosis” FREE on Amazon: https://amazon.com/dp/B07WP7H5LK It's about 5 people with MS who live incredible lives, the science and psychology of resilience, mindfulness, and ho’oponopono. Paperback priced to generate $0 royalty. Dr. Brandon Beaber is a board-certified neurologist with subspecialty training in multiple sclerosis and other immunological diseases of the nervous system. He is a partner in the Southern California Permanente Medical Group and practices in Downey, California (South Los Angeles). He has several publications on MS epidemiology and has participated in clinical trials for MS therapeutics. You can follow him on twitter @Brandon_Beaber where he regularly posts about MS news and research. Follow me on twitter:   / brandon_beaber   Music: INNER GRACE - Copyright 2018 Wilton Vought Source: Really Really Free Music Link:    • Видео   T he video material by Dr. Brandon Beaber is general educational material on health conditions and is not intended to be used by viewers to diagnose or treat any individual's medical condition. Specifically, this material is not a substitute for individualized diagnostic and treatment advice by a qualified medical/health practitioner, licensed in your jurisdiction, who has access to the relevant information available from diagnostic testing, medical interviews, and a physical examination. To the extent that Dr. Beaber endorses any lifestyle change, behavioral intervention, or supplements, the viewer should consult with a qualified healthcare professional to determine the safety and efficacy of the intervention in light of their individualized information.

Comments